市值蒸发三千亿 陈邦身家缩水1145亿 爱尔眼科“闯关”港股

This article outlines the current situation and latest developments of Aier Eye, China’s leading private ophthalmology provider. Key takeaways are as follows:

1. Core event: Aier Eye has completed a self-inspection over historical tax non-compliance, paying 524 million yuan in back taxes and late fees. The full amount will be recorded as a current-period loss in 2026, equal to 16% of the company’s full-year 2025 net profit. The issue only impacts 2026 profit and will not require restatement of prior-year financial results. The discrepancy arose from management challenges stemming from the company’s vast network of branches, inconsistent regional tax enforcement, and the exposure of previously hidden gaps after the launch of China’s Golden Tax Project IV.

2. Current operating status: The company’s market cap has shrunk by more than 300 billion yuan from its 2021 peak, and controlling shareholder Chen Bang’s net worth has declined by 114.5 billion yuan. 2025 marked the first year of net profit decline since the company went public, with 9.5 billion yuan in goodwill on its books carrying hidden impairment risks. The acquisition fund model that supported its past expansion has officially ended.

3. Future plans: Aier has officially submitted a prospectus to the Hong Kong Stock Exchange to pursue a dual listing there, planning to leverage the Hong Kong platform to expand its overseas business and build a new growth engine.

This article offers valuable industry insights and lessons for healthcare brand operators, with key takeaways as follows:

1. Industry competition and consumer trends: The core high-margin refractive surgery segment has shifted from serving primarily high-end consumers to the mass market, putting persistent downward pressure on per-customer pricing. Intensifying price wars among peers, combined with医保控费 and consumable bulk purchasing policies, have steadily compressed profit margins for traditional core businesses. Brands need to adjust their business structure proactively to adapt to these changes.

2. Lessons from expansion models: Aier Eye used its early "listed company + PE" acquisition fund model to quickly leverage capital and complete its national layout, but this model left behind substantial goodwill risks. With the pool of high-quality domestic acquisition targets now exhausted, the model has fulfilled its historical purpose. This demonstrates that brand expansion should not rely solely on capital-fueled scale growth, and needs to place greater focus on quality of growth.

3. Directions for breaking through: After saturating the domestic market, brands can pursue overseas expansion to unlock new growth. At the same time, brands must prioritize compliance, proactively resolve historical issues, and meet the compliance requirements of both capital markets and regulators.

This article discloses the latest shifts in the ophthalmology medical services sector, providing clear opportunity and risk alerts for relevant industry practitioners, with key insights as follows:

1. Policy reminder: Golden Tax Project IV is now fully implemented, marking a new era of data-driven tax regulation with interconnected data across multiple government agencies. Previously hidden tax loopholes are now being identified, and all operators should proactively conduct self-inspections and pay back taxes to avoid harsher regulatory penalties down the line.

2. Market opportunity: China’s tier-1 and tier-2 ophthalmology markets have largely become saturated, and the payback period for new county-level clinics continues to extend. By contrast, overseas markets still have substantial room for growth. In 2025, Aier Eye’s overseas revenue grew 16.47% year-over-year, far outpacing the growth rate of its domestic business. Going global is a new growth direction that deserves close attention.

3. Risk alert: The industry is facing intensifying price wars that are pushing down core business gross margins, while rent and labor costs continue to rise. A substantial goodwill impairment would significantly erode profits. Overseas operations also face multiple risks including compliance issues, local competition, and exchange rate volatility, requiring proactive operational and risk management preparation.

This article offers operational and strategic insights for factories across the ophthalmology healthcare supply chain, with key takeaways as follows:

1. Shifts in product design and demand: As domestic refractive surgery penetration continues to rise and the consumer base expands from high-end to mass markets, demand for cost-effective ophthalmology consumables and equipment will grow steadily. Factories can proactively build high-cost-effective product lines tailored to the mass market to capture this growing demand.

2. Commercial opportunity: As China’s leading ophthalmology provider, Aier Eye has made globalization a core strategic priority and will continue acquiring medical institutions both domestically and abroad, driving steady demand for upstream consumables and equipment. Factories can seize partnership opportunities and expand their overseas market share by aligning with the leading player’s expansion.

3. Insights for digital transformation: The launch of Golden Tax Project IV has pushed the entire industry into an era of digital regulation. Factories should also accelerate internal digital management upgrades to improve compliance in finance, taxation and other operational areas, while optimizing internal management efficiency to offset the pressure of persistently rising labor costs.

This article outlines the latest development trends of the ophthalmology medical service industry, providing clear industry insights and market opportunities for relevant service providers, with key takeaways as follows:

1. Industry development trends: China’s private ophthalmology industry has transitioned from a period of capital-driven rapid expansion to a new phase of stock competition and transformation. Leading players have universally made globalization a core strategy and are looking overseas to unlock new growth curves, putting the entire industry at a critical transformation juncture.

2. Core pain points for clients: Leading healthcare enterprises currently face three core pain points. First, expansion into a large network of branches has drastically increased internal management difficulty, making compliance risks such as taxation far more prominent. Second, domestic growth has slowed, and the original acquisition-driven expansion model no longer works, leaving enterprises urgently needing to find new growth paths. Third, global operations face multiple challenges ranging from compliance and management to local competition.

3. Market opportunities: Service providers can develop tailored solutions to address these pain points. This includes building digital compliance management systems for multi-branch chain medical enterprises, as well as offering overseas compliance consulting and localized operation consulting services to match the service needs of leading enterprises pursuing global expansion.

Drawing on the case of Aier Eye’s upcoming Hong Kong IPO, this article offers valuable insights for all types of capital and industry platforms, with key takeaways as follows:

1. Corporate demand for platforms: Leading domestic players that have completed their national布局 now普遍 have global expansion demand after saturating the domestic market, and need international capital platforms to provide financing and cross-border capital operation support. Aier’s Hong Kong listing is intended to build an international capital platform to support overseas acquisitions, reflecting clear demand from leading expansion-focused companies for international platforms.

2. Insights for platform operations and management: The Hong Kong Stock Exchange sets compliance as a hard requirement for listing, prompting companies to proactively resolve historical compliance issues ahead of their IPO. Platforms should prioritize compliance audits in their outreach and vetting processes, especially tax compliance, to proactively identify risks and maintain market order on the platform.

3. Risk mitigation guidance: Long-term capital-driven acquisition expansion can accumulate asset risks such as substantial goodwill. Platforms need to pay close attention to the asset quality of listed firms, improve information disclosure requirements, proactively alert the market to risks, and avoid systemic risks at the platform level.

This article provides a typical research case for the development of the private healthcare services industry and outlines the latest industry trends, with key research references as follows:

1. New industry trends: China’s private ophthalmology medical services industry has ended its period of capital-driven rapid expansion and land-grabbing, and officially entered a new development phase of stock competition and global transformation. Leading players have elevated globalization to a core strategic priority and are pursuing new growth curves overseas, putting the entire industry into a new development cycle.

2. New research questions: After the full implementation of Golden Tax Project IV, what new challenges does compliance management face for multi-branch chain enterprises? What is the pattern and impact of diminishing marginal returns for capital-driven acquisition expansion after domestic market saturation? What difficulties do chain medical enterprises face when expanding overseas, and can an A+H dual listing model resolve growth bottlenecks? All of these are new topics that deserve in-depth research.

3. Business model research sample: Aier Eye’s pioneering early "listed company + PE" acquisition fund model once drove rapid industry expansion, but the model has now fulfilled its historical purpose, with new expansion models still under exploration. This makes it a canonical sample for researching the evolution of business models in the chain medical services industry.